My watch list

Mitiglinide


Mitiglinide
Systematic (IUPAC) name
(-)-2(S)-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
Identifiers
CAS number	207844-01-7
ATC code	A10BX
PubChem	121891
Chemical data
Formula	C₁₉H₂₅NO₃
Mol. mass	315.41 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	oral

Mitiglinide (trade name Glufast®) is a drug for the treatment of type 2 diabetes.

Additional recommended knowledge

Weighing the right way

Don't let static charges disrupt your weighing accuracy

Correct Test Weight Handling Guide: 12 Practical Tips

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells

Dosage

Mitiglinide is delivered in tablet form.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose
Thiazolidinediones (TZD)	Pioglitazone, Rosiglitazone, Troglitazone
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Saxagliptin, Sitagliptin, Vildagliptin
Glucagon-like peptide-1 analog	Exenatide
Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), intermediate-acting (NPH insulin), long acting (Insulin glargine, Insulin detemir)